MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-10-2023
Syneos Health Operating Income 2011-2026 | SYNH
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Syneos Health
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 389 M | 293 M | 238 M | 160 M | -28.9 M | 155 M | 152 M | 63.6 M | 31.5 M | -37.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 389 M | -37.5 M | 142 M |
Quarterly Operating Income Syneos Health
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -39.5 M | - | - | - | 73.9 M | - | 113 M | 83.7 M | 61 M | - | 98.8 M | 35 M | 49 M | 83.4 M | 69.4 M | 58.1 M | 26.8 M | 79.5 M | 39.8 M | 30.7 M | 10.2 M | 15 M | -88.9 M | 10.2 M | 34.8 M | 43.8 M | 39.4 M | 39.7 M | 32.5 M | 39.7 M | 44.3 M | 35.9 M | 32.4 M | 18.5 M | 22.7 M | 7.87 M | 14.6 M | 11.3 M | 15 M | 4.79 M | 370 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 113 M | -88.9 M | 34.6 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Agilent Technologies
A
|
1.35 B | $ 115.55 | 3.81 % | $ 35.1 B | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 20.81 | 0.05 % | $ 1.11 B | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 1.55 | 1.31 % | $ 2.06 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 24.49 | 1.03 % | $ 680 M | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 15.19 | 2.64 % | $ 459 M | USA |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 118.33 | 1.86 % | $ 9.76 B |  Irlanda |
 |
Illumina
ILMN
|
-833 M | $ 126.74 | 5.29 % | $ 20.2 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 166.97 | 1.91 % | $ 8.28 B | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 84.62 | 4.25 % | $ 5.71 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 418.66 | 1.23 % | $ 12.1 B | USA |
 |
Guardant Health
GH
|
-437 M | $ 87.08 | 4.4 % | $ 10.9 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 26.34 | 2.95 % | $ 20 B |  Niderland |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.75 | 1.5 % | $ 440 M | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 1.98 | -0.5 % | $ 8.76 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 9.26 | 3.35 % | $ 1.19 B | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.18 | 0.93 % | $ 5.01 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 256.8 | -0.13 % | $ 21.4 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 16.46 | -0.48 % | $ 368 M | USA |
 |
Celcuity
CELC
|
-172 M | $ 121.35 | 1.97 % | $ 5.67 B | USA |
 |
Natera
NTRA
|
-541 M | $ 206.16 | 5.86 % | $ 20.3 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.4 | 4.33 % | $ 2.04 B | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 194.2 | 2.58 % | $ 21.6 B | USA |
 |
OpGen
OPGN
|
325 K | - | -16.95 % | $ 1.54 M | USA |
 |
Organovo Holdings
ONVO
|
-12.6 M | - | -2.3 % | $ 19.4 M | USA |
 |
PerkinElmer
PKI
|
357 M | - | -0.91 % | $ 14.7 B | USA |
 |
Exagen
XGN
|
-14.1 M | $ 2.9 | 5.07 % | $ 62.5 M | USA |
 |
Precipio
PRPO
|
-1.2 M | $ 30.9 | 3.21 % | $ 49.6 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 17.0 | 4.68 % | $ 179 M | China |
 |
Personalis
PSNL
|
-68.3 M | $ 5.52 | 9.52 % | $ 327 M | USA |